HomeAI · summaries
Storia in 20 fonti
Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA
FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancer. Phase 3 trials show a 60% reduced death risk vs chemotherapy.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly…
- ·
healio.com
Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma
The FDA has approved a first-in-class targeted therapy for adults with metastatic pancreatic adenocarcinoma. Daraxonrasib (Rasonque, Revolution Medicines), an RAS inhibitor,…
